The approval two CAR T-cell therapies for relapsed \/ refractory B-cell hematological malignancies\u2014Novatis\u2019 Kymriah for acute lymphoblastic leukemia (ALL) and large B-cell lymphoma and Kite Pharma \/ Gilead\u2019s Yescarta for large B-cell lymphoma\u2014heralded a new era in cancer immunotherapy. Multiple myeloma, another hematological malignancy, is set to follow suit in 2021 and 2022 with the expected approval of BCMA-targeting CAR T-cell therapies, including bluebird bio\/Celgene\u2019s idecabtagene vicleucel and Janssen\u2019s ciltacabtagene autoleucel (cilta-cel). We explore how payers approach reimbursement of CAR T-cell therapies for B-cell ALL and multiple myeloma and how reimbursement decisions impact therapy selection and prescribing among surveyed hematologist-oncologists.<\/p>\n
QUESTIONS ANSWERED<\/p>\n
\u00b7 What role do CAR T-cell therapies play in the treatment of multiple myeloma and B-cell ALL?<\/p>\n
\u00b7 What are hematologist-oncologists’\u00a0experience with the use of Kyrmiah so far?<\/p>\n
\u00b7 What strategies will payers use to control utilization and costs of CAR T-cell therapies as more come to market?<\/p>\n
\u00b7 What are hematologist-oncologists\u2019 views on select emerging CAR T-cell therapies in late-phase development?<\/p>\n
GEOGRAPHY:<\/strong> United States.<\/p>\n PRIMARY RESEARCH:<\/strong> Survey of 56 U.S. hematologist-oncologists and 40 U.S. managed care organization (MCO) pharmacy directors and medical directors (PDs\/MDs).<\/p>\n KEY DRUGS COVERED:<\/strong> Kymriah, Besponsa, Blincyto, Blenrep, Tecartus, idecabtagene vicleucel (ide-cel), ciltacabtagene autoleucel (cilta-cel)<\/p>\n CONTENT HIGHLIGHTS:<\/strong><\/p>\n\n